Kenji M. Fujihara

Grattan Street
Parkville, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy.

Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy.

Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026

Targeting DNA Polymerase Epsilon Leads to Tumor Clearance and Activation of an NF-κB-mediated inflammatory response in Triple Negative Breast Cancer.

Targeting DNA Polymerase Epsilon Leads to Tumor Clearance and Activation of an NF-κB-mediated inflammatory response in Triple Negative Breast Cancer.

Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025

Redox cycling nitroxide limits cellular iron availability and selectively inhibits iron-sulfur cluster metabolism.

Redox cycling nitroxide limits cellular iron availability and selectively inhibits iron-sulfur cluster metabolism.

Journal: Cell death discovery
Published: June 16, 2025

Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-κB-Mediated Inflammatory Response in Triple-Negative Breast Cancer.

Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-κB-Mediated Inflammatory Response in Triple-Negative Breast Cancer.

Journal: Cancer research
Published: May 23, 2025

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction.

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction.

Journal: Science advances
Published: September 14, 2022

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Journal: Cell death & disease
Published: August 03, 2022

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Journal: Cancers
Published: July 12, 2022

Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.

Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.

Journal: Annals of surgery
Published: June 23, 2022

Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle.

Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle.

Journal: Nature metabolism
Published: June 22, 2022

Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes.

Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes.

Journal: ACS chemical biology
Published: June 13, 2022

Tumor-Infiltrating Neutrophils after Neoadjuvant Therapy are Associated with Poor Prognosis in Esophageal Cancer.

Tumor-Infiltrating Neutrophils after Neoadjuvant Therapy are Associated with Poor Prognosis in Esophageal Cancer.

Journal: Annals of surgical oncology
Published: March 28, 2022

Sideroflexin 4 is a complex I assembly factor that interacts with the MCIA complex and is required for the assembly of the ND2 module.

Sideroflexin 4 is a complex I assembly factor that interacts with the MCIA complex and is required for the assembly of the ND2 module.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 25, 2022
Showing 1-12 of 25

Last Updated: 09/26/2026